Routine Platelet Testing Should Not Be Performed on All Patients Undergoing Percutaneous Coronary Intervention
نویسندگان
چکیده
منابع مشابه
Should routine platelet testing be done on all patients undergoing percutaneous coronary intervention? Routine Platelet Testing Should Not Be Performed on All Patients Undergoing Percutaneous Coronary Intervention
We all know that clopidogrel reduces thrombotic complications during and after a percutaneous coronary intervention (PCI) procedure. Because clopidogrel is a prodrug and only 2% of ingested clopidogrel is ultimately bound to platelets, it is entirely possible, even likely, that small differences in metabolism that lead to a reduction in the formation of the active metabolite could potentially h...
متن کاملShould routine platelet testing be done on all patients undergoing percutaneous coronary intervention? The Evidence Base for Platelet Function Testing in Patients Undergoing Percutaneous Coronary Intervention
The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. From the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, Calif. This article is Part I of a 2-part series. Part II appears on page 284. Correspondence to Matthew J. Price, MD, 10666 N Torrey Pines Rd, Maildrop S1056, La Jolla, CA 92037. E-mail price.matthew@scripp...
متن کاملShould Genetic Testing Be Done in All Patients Treated With Clopidogrel and Undergoing Percutaneous Coronary Intervention? CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention
Clopidogrel when added to aspirin reduces major vascular events in patients undergoing percutaneous coronary intervention (PCI).1 Recent reports have suggested that common genetic variants involving hepatic cytochrome P450 system enzymes that convert clopidogrel to its active metabolite are associated with an increased risk of cardiovascular events. Specifically, patients who are carriers of 1 ...
متن کاملShould Genetic Testing Be Done in All Patients Treated With Clopidogrel and Undergoing Percutaneous Coronary Intervention? Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting
A combined dual antiplatelet treatment consisting of aspirin and the P2Y12 receptor inhibitor clopidogrel is still considered the standard of care treatment in most of the patients undergoing percutaneous coronary intervention (PCI). Numerous research studies during the last decade, however, have highlighted possible shortcomings of the oral antiplatelet agent clopidogrel, namely its large resp...
متن کاملExpert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention
Department of Cardiology, Heart Center Balatonfüred, 2 Gyógy tér, Balatonfüred 8230, Hungary; Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; Universityof Pécs,Heart Institute, Pécs, Hungary; Universitäts-Herzzentrum Freiburg-Bad Krozingen, Klinik für Kardiologie und Angiologie II, Bad Krozingen, Germany; Department for Internal Medicine and Cardiology, KKO St Mari...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation: Cardiovascular Interventions
سال: 2010
ISSN: 1941-7640,1941-7632
DOI: 10.1161/circinterventions.110.950972